viewSnap Inc

UBS hikes Snap to Buy and raises price target to $24 on ‘momentum’

Analysts expect Snap to keep increasing its ad revenue and user growth into the new year

Snap Inc - UBS hikes Snap to Buy and raises price target to $24 on 2020 ‘momentum’
The Swiss bank had a Neutral rating on Snap and a $16 price target

Analysts at UBS have raised Snap Inc (NASDAQ:SNAP) to a Buy and its price target to $24, saying the company has strong “momentum” heading into 2020. 

The Swiss bank had a Neutral rating on Snap, the parent company of social media app Snapchat, with a $16 price target. The company’s stock recently rose by 4% to $19.01 a share in New York. 

“Inline with recent quarters, we see SNAP exiting 2019 with positive business momentum in terms of both ad revenue and user growth and expect such momentum to persist in 2020,” its analysts wrote. 

READ: Snap beats Street's 3Q revenue and profit estimates

“While the stock is up 21% over the past month and certainly not a contrarian idea to upgrade at these levels, we see a renewed management team focused on driving a mix of user growth (especially the Android refresh) and ad monetization that could produce multiyear revenue growth even above our newly raised forecasts,” they added.

The analysts also pointed out that data from the UBS Evidence Lab Social Media survey of more than 2,000 US internet users indicate "strong YoY growth in usage (particularly outside of Snap's core demo) and ad conversion.”

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Snap Inc


Price: 78.6 USD

Market Cap: $124.27 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Ixico seeing success with a number of contracts awarded covering multiple...

Ixico plc Chief Commercial Officer Lammert Albers joined Steve Darling from Proactive to share news the Clinical Research Organization has awarded the company, on behalf of their biopharmaceutical sponsor,  a 6-figure deal to conduct a Phase II Alzheimer’s disease clinical trial.  Albers...

4 hours, 33 minutes ago

2 min read